by James Lyons-Weiler, PhD, Popular Rationalism, ©2025
(Dec. 5, 2025) — In a December 5, 2025 vote, ACIP removed the long‑standing universal recommendation that every newborn in the United States receive the first dose of Hepatitis B vaccine (HepB) at birth. Instead, the panel adopted a “shared clinical decision‑making” approach: infants born to mothers who test positive for HBsAg or whose status is unknown still receive the birth dose; for infants of mothers who test negative, parents and health‑care providers now decide together whether to vaccinate at birth — with a suggested option to begin the schedule no earlier than two months of age.
This shift can be viewed as a correction toward a more risk‑stratified, individualized public‑health strategy — one that recognizes that universal birth‑dose policy implicitly treats all newborns the same regardless of maternal risk. By deferring to maternal screening results and parent‑clinician discretion, the new guidance reduces the blanket exposure of all neonates to a medical intervention whose primary benefit is contingent on maternal infection status and on preventing perinatal transmission. In effect, it seeks to limit medical intervention to those infants for whom the benefit is most clear, thereby better aligning with a “first, do no harm” ethic.
Supporters argue this decision empowers parental autonomy and acknowledges that the residual risk of perinatal hepatitis B among infants born to HBsAg‑negative mothers is extremely low — particularly when prenatal screening is performed. They contend that in a modern health‑care context with widespread prenatal screening and reduced population HBV prevalence, mandated universal birth dosing may no longer be justified as a public‑health default. The ACIP vote thus represents a long‑overdue reappraisal of one‑size‑fits‑all vaccination policy in favor of choice, risk‑stratification, and individualized medical decision‑making.
HepB Vaccine at a Crossroads: A Long Overdue Reckoning
The debate over newborn hepatitis B vaccination has finally broken into public view. For over thirty years, the recommendation to vaccinate all newborns against hepatitis B within hours of birth has stood largely unchallenged. Unsupported by any study that showed general benefit in terms of later immunity, it was cemented into pediatric norms by inertia and institutional authority. Today, with the CDC’s Advisory Committee on Immunization Practices (ACIP) publicly split, and HHS under Robert F. Kennedy, Jr. opening the door to science-grounded dissent, the moment arrived for a long overdue and proper reckoning.
At issue is not whether hepatitis B infection can be serious. It can be. Nor is it about whether vaccines in general prevent disease. The real question is whether we are ethically and epidemiologically justified in requiring a biologically non-risk-bearing newborn to receive an invasive intervention that does not benefit them directly. Especially when the intervention carries nonzero, if rare, risk.
The Hepatitis B virus primarily transmitted through sexual contact, needle sharing, and perinatal exposure from infected mothers. In infants born to HBsAg-negative mothers, the immediate risk of hepatitis B infection is not zero, but it is vanishingly small. This has long been the rationale for universal screening of pregnant women. However, in practice, gaps in screening, false-negative results, and inconsistent follow-up have been cited to justify a safety-net policy: vaccinate everyone, just in case.
The counterargument, gaining ground at ACIP, is rooted in balance-of-risk thinking. A November 2025 model published by Abers, Ulrich, and Walensky in JAMA doi:10.1001/jama.2025.24996 estimates that under perfect maternal screening, restricting the birth dose to infants of HBsAg-positive mothers would result in only 58 additional perinatal infections annually in the United States—an absolute risk difference of just 1 per 62,000 infants vaccinated at birth.
Read the rest here.
Copied from Truth Social website:
